Gata3 antagonizes cancer progression in Pten-deficient prostates.
暂无分享,去创建一个
P. Pandolfi | A. Mes-Masson | F. Saad | M. Bouchard | J. Haigh | M. Paquet | K. Haigh | Mathieu Tremblay | A. T. Nguyen | I. Koumakpayi | Katharina Haigh
[1] L. Tran,et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. , 2011, Cancer cell.
[2] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[3] F. Grosveld,et al. Gata3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm2. , 2010, The Journal of clinical investigation.
[4] F. Saad,et al. PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.
[5] Brian J. Wilson,et al. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis , 2009, Oncogene.
[6] M. Bouchard,et al. Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases. , 2009, The Journal of clinical investigation.
[7] G. Berx,et al. Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells , 2009, Nucleic acids research.
[8] L. Pelliniemi,et al. Lack of Gata3 results in conotruncal heart anomalies in mouse , 2009, Mechanisms of Development.
[9] M. Bouchard,et al. Gata3 Acts Downstream of β-Catenin Signaling to Prevent Ectopic Metanephric Kidney Induction , 2008, PLoS genetics.
[10] L. Zhao,et al. Class I PI3K in oncogenic cellular transformation , 2008, Oncogene.
[11] Z. Werb,et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. , 2008, Cancer cell.
[12] J. Diallo,et al. NOXA and PUMA Expression Add to Clinical Markers in Predicting Biochemical Recurrence of Prostate Cancer Patients in a Survival Tree Model , 2007, Clinical Cancer Research.
[13] M. Shen,et al. Pten inactivation and the emergence of androgen-independent prostate cancer. , 2007, Cancer research.
[14] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[15] Marie-Liesse Asselin-Labat,et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation , 2007, Nature Cell Biology.
[16] Zena Werb,et al. GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland , 2006, Cell.
[17] Paulo A. S. Nuin,et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. , 2006, Cancer Genetics and Cytogenetics.
[18] H. Stoop,et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi‐allelic gene deletion , 2006, The Journal of pathology.
[19] B. Park,et al. Mutation of the PIK3CA oncogene in human cancers , 2006, British Journal of Cancer.
[20] B. Vanhaesebroeck,et al. Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[21] M. Busslinger,et al. Pax2/8-regulated Gata3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney , 2006, Development.
[22] B. Vanhaesebroeck,et al. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[23] John T. Wei,et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.
[24] R. Tibshirani,et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[25] P. Pandolfi,et al. Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.
[26] P. Nelson,et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.
[27] Kenneth M. Murphy,et al. Decision making in the immune system: The lineage decisions of helper T cells , 2002, Nature Reviews Immunology.
[28] J. McGhee,et al. The GATA family (vertebrates and invertebrates). , 2002, Current opinion in genetics & development.
[29] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.
[30] M. Bittner,et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.
[31] P. Roy-Burman,et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.
[32] Bernard A. Roos,et al. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer , 2000, Molecular and Cellular Endocrinology.
[33] Rajesh V. Thakker,et al. GATA3 haplo-insufficiency causes human HDR syndrome , 2000, Nature.
[34] James Douglas Engel,et al. Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system , 2000, Nature Genetics.
[35] J. Herman,et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.
[36] James Douglas Engel,et al. Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis , 1995, Nature Genetics.